Jiangsu Bioperfectus Technologies Co., Ltd.

(SSE:688399)

BioPerfectus, a public listed company at Shanghai Stock Exchange (SSE:688399), is one of the leading molecular diagnostic solution providers specialized in infectious diseases ever since 2010. With headquarter located in Jiangsu, subsidiaries in Shanghai, Beijing, Xi’an, Taizhou, Hainan and Yinchuan. Bioperfectus is pioneering in molecular diagnostics market with our products ranging from real time PCR kits, nucleic acid extraction systems, rapid tests and automation laboratory devices. Young and passionate, Bioperfectus people are working steadily and firmly to achieve our dream to create a healthier future for our next generations.

62,000+㎡

An industrial park of over 62,000㎡ integrating fully self-innovative R&D, production, warehousing, logistics, sales, marketing and customer service divisions catering for various business scenarios

600+

Over 600 Bioperfectus people’s permission gathering the perseverance and determination to fight against the global pandemic

5,000,000+

Production capacity ramping up to more than 5 million tests/day ensuring the quick sufficient response to infectious diseases

global presence

80 Countries within a year

Bioperfectus Products & Service have been distributed to over 80+ countries around the globe within only one year since the international business established.

10000 Machinery spots

Bioperfectus Nucleic Acid Extraction Solutions
were launched in over 10,000 laboratories
globally with a well-trained and quick-response
customer service team.

Product Center

News Center

12-312021

Bioperfectus 2021 Special Review: Goodbye 2021, Hello 2022

12-312021

2021 has been an exceptional year for Bioperfectus. We have successfully achieved many milestones by supplying our molecular diagnostic products to where people need them most. The glorious stories and moments shaped 2021 of Bioperfectus, now come and follow us for our special #2021Review. Section 1. Product Manufacturing 1. New product launch In the year 2021, we have launched 33 products in total out of our 7 product pipelines. In the Respiratory Infectious Diseases pipeline, we ...

12-282021

Bioperfectus Obtained CE Mark for the SARS-CoV-2 Antigen Rapid Self-test

12-282021

Bioperfectus is pleased to announce that we have obtained CE Mark for our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test). This test is a lateral flow test intended for non-prescription home use with self-collected nasal swab specimens. It is used to detect symptomatic individuals who are suspected of COVID-19 or asymptomatic individuals who have had contact with confirmed COVID-19 patients but do not show any symptoms. Our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit w...

12-272021

Bioperfectus Launches a New RT-PCR Kit to Detect COVID-19 New Variant"Omicron"

12-272021

On Nov. 24, 2021, the variant B.1.1.529 was first identified in South Africa, and only two days later, WHO announced that B.1.1.529 constitutes a variant of concern, named Omicron. For now, the spread of Omicron is much faster, even than the Delta variant. Eighty-three countries and regions with 33460 Omicron cases have been reported on the GISAID website on Dec. 24, 2021. The data only shows the number of submitted sequenced cases and more samples are in the works. According to the CDC, ...

Learn More

Service Network

Support is only one step away

A good after-sales service is essential for efficiency of workload in PCR laboratory. Bioperfectus delivers most perfect service via our authorized distributors and global service center. With well-experienced service staff, sufficient spare-part inventory and fast global logistics, Bioperfectus aims to provide with the satisfactory solutions to our end users.We offer 24/7 after-sales service, prompt response and periodical training programs.

CONTACT US NOW